The suppliers of a new drug to treat anemia in patients undergoing kidney dialysis have recalled all lots of the product after reports that it had caused severe allergic reactions, including some that were fatal.
Affymax and Takeda Pharmaceutical jointly marketed the drug Omontys. Both companies and the F.D.A. said the reactions occurred within 30 minutes of patients receiving their first dose by intravenous administration. The F.D.A. and both companies have advised that Omontys use be discontinued.